Hong Kong Pharmaceuticals & Biotech Stable Growth Stocks

3SBio

Market Cap: HK$44.4b

An investment holding company, engages in the development, production, marketing, and sale of biopharmaceutical products in the People’s Republic of China, the United States, and internationally.

Hansoh Pharmaceutical Group

Market Cap: HK$200.6b

An investment holding company, engages in the research, development, production, and sale of pharmaceutical products in the People’s Republic of China.

China Resources Pharmaceutical Group

Market Cap: HK$30.2b

An investment holding company, engages in the manufacture, distribution, and retail of pharmaceutical and other healthcare products in Mainland China and internationally.

Biocytogen Pharmaceuticals (Beijing)

Market Cap: HK$59.8b

A biotechnology company, engages in the research and development of novel antibody-based drugs and pre-clinical research services in the People’s Republic of China, the United States, and internationally.

WuXi Biologics (Cayman)

Market Cap: HK$209.3b

An investment holding company, provides end-to-end solutions and services for biologics discovery, development, and manufacturing for biologics industry in the People’s Republic of China, North America, Europe, Singapore, Japan, South Korea, Australia, and Brazil.